Mumbai, India
Glenmark Pharmaceuticals, founded in 1977, is a research-driven, global, integrated pharmaceutical company with headquarters in Mumbai, India. The company has evolved from being a generics manufacturer to offering specialty and branded products. Its business spans over 80 countries with a strong focus on dermatology, respiratory, and oncology.
Glenmark operates ten state-of-the-art manufacturing facilities across four continents, reinforcing its global reach. The formation of Ichnos Glenmark Innovation (IGI) emphasized its commitment to accelerating cancer treatment innovations by partnering with its subsidiary, Ichnos Sciences.
Although their last investment was a Post IPO Equity investment in August 2018 by True North Managers, Glenmark remains a compelling candidate for investors. Glenmark demonstrates considerable focus on ESG goals and community impact, with its CSR efforts benefiting over 3 million people.
